Elevation Oncology (ELEV)
(Real Time Quote from BATS)
$2.91 USD
+0.02 (0.69%)
Updated Jul 26, 2024 03:52 PM ET
After-Market: $2.94 +0.03 (1.03%) 4:18 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ELEV 2.91 +0.02(0.69%)
Will ELEV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ELEV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELEV
Are Medical Stocks Lagging Elevation Oncology (ELEV) This Year?
ELEV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ELEV
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
Elevation Oncology (ELEV) Receives a Buy from TD Cowen
Elevation Oncology’s EO-3021: A Promising Candidate in the Treatment Landscape for GEJ and GC
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer
Elevation Oncology to evaluate combination in gastroesophageal junction cancer